Leonard Haas1, Rachel Chevalier2, Brittny T Major3, Felicity Enders3, Seema Kumar4, Jeanne Tung5. 1. Mayo Medical School, Rochester, MN, USA. 2. Department of Pediatrics, Childrens Mercy Hospital, Kansas City, MO, USA. 3. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA. 4. Division of Pediatric Endocrinology, Mayo Clinic, Rochester, MN, USA. 5. Division of Pediatric Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. tung.jeanne@mayo.edu.
Abstract
BACKGROUND: Children with active inflammatory bowel disease (IBD) are frequently underweight. Anti-tumor necrosis factor (anti-TNF) agents may induce remission and restore growth. However, its use in other autoimmune diseases has been associated with excess weight gain. Our aim was to examine whether children with IBD could experience excess weight gain. METHODS: A centralized diagnostic index identified pediatric IBD patients evaluated at our institution who received anti-TNF therapy for at least 1 year between August 1998 and December 2013. Anthropometric data were collected at time of anti-TNF initiation and annually. Excess weight gain was defined as ΔBMI SDS (standard deviation score) where patients were (1) reclassified from "normal" to "overweight/obese," (2) "overweight" to "obese," or (2) a final BMI SDS >0 and ΔSDS >0.5. RESULTS: During the study period, 268 children received anti-TNF therapy. Of these, 69 had sufficient follow-up for a median of 29.3 months. Median age at first anti-TNF dose was 12.8 years. At baseline, mean weight SDS was -0.7 (SD 1.4), while mean BMI SDS was -0.6 (1.3). Using baseline BMI SDS, 11.6% were overweight/obese. At last follow-up (LFU), however, the mean ΔBMI SDS was 0.50 (p < 0.0001). However, 10 (17%) patients had excess weight gain at LFU; 3 patients were reclassified from "normal" to "obese," and 7 had a final BMI SDS >0 and ΔSDS >0.5. CONCLUSIONS: Pediatric patients with IBD may experience excess weight gain when treated with anti-TNF agents. Monitoring for this side effect is warranted.
BACKGROUND:Children with active inflammatory bowel disease (IBD) are frequently underweight. Anti-tumornecrosis factor (anti-TNF) agents may induce remission and restore growth. However, its use in other autoimmune diseases has been associated with excess weight gain. Our aim was to examine whether children with IBD could experience excess weight gain. METHODS: A centralized diagnostic index identified pediatric IBD patients evaluated at our institution who received anti-TNF therapy for at least 1 year between August 1998 and December 2013. Anthropometric data were collected at time of anti-TNF initiation and annually. Excess weight gain was defined as ΔBMI SDS (standard deviation score) where patients were (1) reclassified from "normal" to "overweight/obese," (2) "overweight" to "obese," or (2) a final BMI SDS >0 and ΔSDS >0.5. RESULTS: During the study period, 268 children received anti-TNF therapy. Of these, 69 had sufficient follow-up for a median of 29.3 months. Median age at first anti-TNF dose was 12.8 years. At baseline, mean weight SDS was -0.7 (SD 1.4), while mean BMI SDS was -0.6 (1.3). Using baseline BMI SDS, 11.6% were overweight/obese. At last follow-up (LFU), however, the mean ΔBMI SDS was 0.50 (p < 0.0001). However, 10 (17%) patients had excess weight gain at LFU; 3 patients were reclassified from "normal" to "obese," and 7 had a final BMI SDS >0 and ΔSDS >0.5. CONCLUSIONS: Pediatric patients with IBD may experience excess weight gain when treated with anti-TNF agents. Monitoring for this side effect is warranted.
Authors: M A Gonzalez-Gay; M T Garcia-Unzueta; A Berja; T R Vazquez-Rodriguez; C Gonzalez-Juanatey; J M de Matias; J Martin; P H Dessein; J Llorca Journal: Ann Rheum Dis Date: 2008-11 Impact factor: 19.103
Authors: Millie D Long; Wallace V Crandall; Ian H Leibowitz; Lynn Duffy; Fernando del Rosario; Sandra C Kim; Mark J Integlia; James Berman; John Grunow; Richard B Colletti; Bess T Schoen; Ashish S Patel; Howard Baron; Esther Israel; George Russell; Sabina Ali; Hans H Herfarth; Christopher Martin; Michael D Kappelman Journal: Inflamm Bowel Dis Date: 2010-12-17 Impact factor: 5.325
Authors: O Borrelli; C Bascietto; F Viola; M Bueno de Mesquita; M Barbato; V Mancini; S Bosco; S Cucchiara Journal: Dig Liver Dis Date: 2004-05 Impact factor: 4.088
Authors: Catharina Schuetz; Pamela Fischer-Posovszky; Klaus-Michael Debatin; Julia Zinngrebe; Barbara Moepps; Thomas Monecke; Peter Gierschik; Ferdinand Schlichtig; Thomas F E Barth; Gudrun Strauß; Elena Boldrin; Carsten Posovszky; Ansgar Schulz; Ortraud Beringer; Eva Rieser; Eva-Maria Jacobsen; Myriam Ricarda Lorenz; Klaus Schwarz; Ulrich Pannicke; Henning Walczak; Dierk Niessing Journal: EMBO Mol Med Date: 2022-02-16 Impact factor: 14.260